A Single-center, Randomized, Double-Blinded, Placebo-Controlled, Phase Ⅱ Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells), in the Subjects From Healthy Aged 18 Years and Above
Latest Information Update: 11 Apr 2022
At a glance
- Drugs Recombinant COVID-19 vaccine - WestVac Biopharma/West China Hospital Sichuan University (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- 11 Apr 2022 New trial record